Publication | Open Access

Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

InflammationAsthmaPlacebo-controlled Phase 2Eosinophilic Airway InflammationAllergyLung InflammationRespiratory DiseasesImmunologyEosinophilic DisorderImmunotherapyMedicineClinical AllergyUncontrolled Moderate-to-severe Asthma